Pharmacy

Sep 6 2018

IONS Stock Price & News – Ionis Pharmaceuticals Inc, lexicon pharmaceuticals.#Lexicon #pharmaceuticals

Ionis Pharmaceuticals Inc. IONS (U.S.: Nasdaq)

Volume 1,201,406
AFTER HOURS Vol 51,365
  • Open 53.55
  • Prior Close 53.07 (11/29/17)
  • 1 Day
  • IONS 4.56%
  • DJIA 1.39%
  • S P 500 0.82%
  • Health Care/Life Sciences 0.01%
    • 11/16/17
    • Press Release

    Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen

    • Press Release
    • 11/09/17
    • Press Release

    Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

    • Press Release
    • 11/08/17
    • Press Release

    Ionis Pharmaceuticals to Present at Upcoming Investor Conferences

    • Press Release
    • 11/07/17
    • Press Release

    ( IONS ) Ionis Pharmaceuticals, Inc. to Host Earnings Call

    • Press Release
    • 11/07/17
    • Press Release

    Ionis Announces Management Transitions

    • Press Release
    • 11/07/17
    • Press Release

    Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2017

    • Press Release
    • 11/06/17
    • Press Release

    Ionis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDA

    • Press Release
    • 11/03/17
    • Press Release

    Ionis Announces Submission of Marketing Authorization Application for Inotersen to the European Medicines Agency

    • Press Release
    • 11/02/17
    • Press Release

    Ionis Presents New Data from NEURO-TTR Study at European ATTR Amyloidosis Meeting

    • Press Release
    • 11/01/17
    • The Wall Street Journal

    As Experimental Treatments Grow, Families Face Tough Choices

    • The Wall Street Journal
    • 11/01/17
    • Press Release

    The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA(R) for the Treatment of Spinal Muscular Atrophy

    • Press Release
    • 11/01/17
    • Press Release

    Ionis to Present Inotersen NEURO-TTR Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting

    • Press Release
    • 10/27/17
    • Press Release

    Ionis and Biogen Win Prestigious Prix Galien Best Biotechnology Product Award for SPINRAZA

    • Press Release
    • 10/27/17
    • Press Release

    Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to Provide Inotersen to Patients with Hereditary TTR Amyloidosis in the U.S.

    • Press Release
    • 10/24/17
    • Press Release

    Ionis Pharmaceuticals to Hold Third Quarter 2017 Financial Results Webcast

    • Press Release
    • 10/18/17
    • Press Release

    Positive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs

    • Press Release
    • 10/18/17
    • Press Release

    Ionis Enters into Collaboration with Seventh Sense Biosystems to Support Development of Improved Blood Collection and Diagnostic Device

    • Press Release
    • 10/15/17
    • Press Release

    Ionis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress

    • Press Release
    • 10/13/17
    • Press Release

    Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer s Disease

    • Press Release
    • 10/05/17
    • Press Release

    Biogen s SPINRAZA(R) (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy

    • Press Release
    • 10/04/17
    • Press Release

    Breakfast Technical Briefing on Drug Makers Stocks — Amarin, Endo, Ionis Pharma, and Teva Pharma

    • Press Release
    • 05/04/17
    • MarketWatch.com

    What to do when your biotechnology stock gets hit by takeover rumors

    • MarketWatch.com
    • 04/12/17
    • Barron s

    Celgene, Biogen to Gain From Higher Prices

    • Barron s
    • 12/27/16
    • The Wall Street Journal

    Ionis and Biogen’s Spinraza Drug Wins FDA Approval

    • The Wall Street Journal
    • 11/17/16
    • MarketWatch.com

    10 biotech companies ripe for a buyout, courtesy of Donald Trump

    • MarketWatch.com
    • 11/07/16
    • The Wall Street Journal

    Biogen, Ionis Shares Up After Positive Study Results

    • The Wall Street Journal
    • 08/01/16
    • MarketWatch.com

    Biogen, Ionis spinal muscular atrophy therapy meets study goal

    • MarketWatch.com
    • 08/01/16
    • WSJ Blogs

    Stocks to Watch: SolarCity, Fleetmatics, Ionis Pharmaceuticals

    • WSJ Blogs
    • 08/01/16
    • The Wall Street Journal

    Biogen, Ionis Spinal Muscular Atrophy Therapy Meets Study Goal

    • The Wall Street Journal
    • 08/01/16
    • Barron s

    Biogen Soars Past $300 Yet Remains Undervalued

    • Barron s
    • 07/09/16
    • Barron s

    Tracing the Roots of Economic Theory Back to France

    • Barron s
    • 06/07/16
    • The Wall Street Journal

    Judge Sides With Gilead Against Merck in Hepatitis C Case

    • The Wall Street Journal
P/E Ratio (TTM)
Market Cap
Public Float
Latest Dividend

Short Interest (11/15/17)

Change from Last

Stock Money Flow

Net Money Flow ($)

Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Competitors IONS

Sangamo Therapeutics Inc.

Alnylam Pharmaceuticals Inc.

Idera Pharmaceuticals Inc.

AstraZeneca PLC ADR

GlaxoSmithKline PLC ADR

Bristol-Myers Squibb Co.

Pfizer Inc.

Sarepta Therapeutics Inc.

Lexicon Pharmaceuticals Inc.

  • More information on IONS
  • Competitor Data Provided By: capital cube

Profile IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates its business through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery.

2855 Gazelle Court

Carlsbad California 92010

Research Ratings Ionis Pharmaceuticals Inc. IONS

Per-Share Earnings, Actuals and Estimates

  • Quarterly
  • Annual

IONS will report FY 2017 earnings on 03/02/2018 IONS will report Q4 earnings on 03/02/2018

Financials Ionis Pharmaceuticals Inc. IONS

Net Income

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided “as is” for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.

Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *